With a focus on combating hyperuricemia, Loncom Pharma's Anti Gout APIs, including innovative compounds like Topiroxostat and Febuxostat, are essential for creating medications that manage gout and its complications. These APIs inhibit xanthine oxidase, the enzyme responsible for uric acid production, thereby providing relief and prevention of gout attacks.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
